Provisional Consent to the Distribution of a New Medicine Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Stavudine 15 mg, 20 mg, 30 mg, 40 mg Capsules Bristol-Myers Squibb Company, Epernon, France and Bristol-Myers Squibb Company, Evansville, Indianna, United States of America Zerit Stavudine 1 mg/mL in 200 mL Powder for oral solution Bristol-Myers Squibb Company, Evansville, Indianna, United States of America Zerit Note: This consent is valid for 2 years from the date of publication of this notice. Dated this 4th day of August 1997. G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on 20 February 1997.